Achilles Therapeutics (ACHL) Set to Announce Earnings on Tuesday

Achilles Therapeutics (NASDAQ:ACHLGet Free Report) will be issuing its quarterly earnings data on Tuesday, April 2nd.

Achilles Therapeutics Trading Up 5.0 %

NASDAQ:ACHL opened at $1.25 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.55 and a quick ratio of 8.55. Achilles Therapeutics has a fifty-two week low of $0.74 and a fifty-two week high of $1.76. The stock’s 50-day moving average is $1.14 and its two-hundred day moving average is $0.96. The stock has a market cap of $50.98 million, a PE ratio of -0.66 and a beta of 1.10.

Institutional Investors Weigh In On Achilles Therapeutics

Large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in Achilles Therapeutics by 25.5% during the first quarter. BlackRock Inc. now owns 266,657 shares of the company’s stock worth $784,000 after purchasing an additional 54,225 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Achilles Therapeutics by 19.6% during the first quarter. Renaissance Technologies LLC now owns 30,533 shares of the company’s stock worth $90,000 after buying an additional 5,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Achilles Therapeutics by 130.8% during the first quarter. Bank of America Corp DE now owns 10,450 shares of the company’s stock worth $31,000 after buying an additional 5,922 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Achilles Therapeutics during the second quarter worth approximately $59,000. Finally, Balyasny Asset Management LLC acquired a new position in shares of Achilles Therapeutics during the third quarter worth approximately $39,000. Institutional investors own 56.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Bank of America reissued an “underperform” rating on shares of Achilles Therapeutics in a research note on Thursday, December 14th.

View Our Latest Analysis on ACHL

About Achilles Therapeutics

(Get Free Report)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

Featured Stories

Earnings History for Achilles Therapeutics (NASDAQ:ACHL)

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.